Increased expression of cyclooxygenase-2 mediates enhanced contraction to endothelin ETA receptor stimulation in endothelial nitric oxide synthase knockout mice

Circulation Research

Volumn 98, Issue 11, 2006, Pages 1439-1445

  Zhou, Yingbi ^a,b   Mitra, Srabani ^a   Varadharaj, Saradhadevi ^a   Parinandi, Narasimham ^a   Zweier, Jay L ^a   Flavahan, Nicholas A ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Arachidonic acid; Endothelin 1(1 31); Prostaglandin H2; Thromboxane A2

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1 DERIVATIVE; ENDOTHELIN 1[1-31]; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR AGONIST; INDOMETACIN; NITRIC OXIDE; PHENYLEPHRINE; PROSTAGLANDIN H2; THROMBOXANE A2; THROMBOXANE A2 DERIVATIVE; THROMBOXANE A2 RECEPTOR; THROMBOXANE B2; UNCLASSIFIED DRUG;

ABDOMINAL AORTA; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM; ENZYME INHIBITION; GENE EXPRESSION; IMMUNOFLUORESCENCE; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SMOOTH MUSCLE CONTRACTION; WESTERN BLOTTING; WILD TYPE; ANIMAL; DRUG EFFECT; IN VITRO STUDY; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ANIMALS; AORTA, ABDOMINAL; ARACHIDONIC ACID; CYCLOOXYGENASE 2; MICE; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE SYNTHASE TYPE III; RECEPTOR, ENDOTHELIN A; THROMBOXANE B2; VASOCONSTRICTION;

EID: 33745382953     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000224120.52792.10     Document Type: Article

References (46)

1. Masaki T, Vane JR, Vanhoutte PM. International Union of Pharmacology nomenclature of endothelin receptors. Pharmacol Rev. 1994;46:137-142.
2. Miyauchi T, Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol. 1999;61:391-415.
3. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
4. Rebuffat P, Malendowicz LK, Neri G, Nussdorfer GG. Endothelin-1[1-31] acts as a selective ETA-receptor agonist in the rat adrenal cortex. Histol Histopathol. 2001;16:535-540.
5. Mazzocchi G, Rossi GP, Malendowicz LK, Champion HC, Nussdorfer GG. Endothelin-1[1-31], acting as an ETA-receptor selective agonist, stimulates proliferation of cultured rat zona glomerulosa cells. FEBS Lett. 2000;487:194-198.
6. Ushio-Fukai M, Nishimura J, Kobayashi S, Kanaide H. Endothelin-1 and endothelin-3 regulate differently vasoconstrictor responses of smooth muscle of the porcine coronary artery. Br J Pharmacol. 1995;114:171-179.
7. Ohuchi T, Kuwaki T, Ling GY, Dewit D, Ju KH, Onodera M, Cao WH, Yanagisawa M, Kumada M. Elevation of blood pressure by genetic and pharmacological disruption of the ETB receptor in mice. Am J Physiol. 1999;276:R1071-R1077.
8. Berthiaume N, Yanagisawa M, Labonte J, D'Orleans-Juste P. Heterozygous knock-out of ET(B) receptors induces BQ-123-sensitive hypertension in the mouse. Hypertension. 2000;36:1002-1007.
9. Murakoshi N, Miyauchi T, Kakinuma Y, Ohuchi T, Goto K, Yanagisawa M, Yamaguchi I. Vascular endothelin-B receptor system in vivo plays a favorable inhibitory role in vascular remodeling after injury revealed by endothelin-B receptor-knockout mice. Circulation. 2002;106:1991-1998.
10. Barton M, Haudenschild CC, d'Uscio LV, Shaw S, Munter K, Luscher TF. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A. 1998;95:14367-14372.
11. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med. 1991;325:997-1001.
12. Vaneckova I, Kramer HJ, Backer A, Vernerova Z, Opocensky M, Cervenka L. Early endothelin-A receptor blockade decreases blood pressure and ameliorates end-organ damage in homozygous Ren-2 rats. Hypertension. 2005;46:969-974.
13. Zeiher AM, Ihling C, Pistorius K, Schachinger V, Schaefer HE. Increased tissue endothelin immunoreactivity in atherosclerotic lesions associated with acute coronary syndromes. Lancet. 1994;344:1405-1406.
14. Boulanger C, Luscher TF. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest. 1990;85:587-590.
15. Vanhoutte PM. Say NO to ET. J Auton Nerv Syst. 2000;81:271-277.
16. Zeiher AM, Goebel H, Schachinger V, Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation. 1995;91:941-947.
17. Kourembanas S, McQuillan LP, Leung GK, Faller DV. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest. 1993;92:99-104.
18. Labonte J, D'Orleans-Juste P. Enhanced or repressed pressor responses to endothelin-1 or IRL-1620, respectively, in eNOS knockout mice. J Cardiovasc Pharmacol. 2004;44(suppl 1):S109-S112.
19. Zhou Y, Dirksen WP, Zweier JL, Periasamy M. Endothelin-1-induced responses in isolated mouse vessels: the expression and function of receptor types. Am J Physiol Heart Circ Physiol. 2004;287:H573-H578.
20. Zhou Y, Varadharaj S, Zhao X, Parinandi N, Flavahan NA, Zweier JL. Acetylcholine causes endothelium-dependent contraction of mouse arteries. Am J Physiol Heart Circ Physiol. 2005;289:H1027-H1032.
21. Wang Y, Wang DH. Prevention of endothelin-1-induced increases in blood pressure: role of endogenous CGRP. Am J Physiol Heart Circ Physiol. 2004;287:H1868-H1874.
22. Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens. 1998;16:1081-1098.
23. Lariviere R, Thibault G, Schiffrin EL. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension. 1993;21:294-300.
24. Lariviere R, Deng LY, Day R, Sventek P, Thibault G, Schiffrin EL. Increased endothelin-1 gene expression in the endothelium of coronary arteries and endocardium in the DOCA-salt hypertensive rat. J Mol Cell Cardiol. 1995;27:2123-2131.
25. Nguyen PV, Parent A, Deng LY, Fluckiger JP, Thibault G, Schiffrin EL. Endothelin vascular receptors and responses in deoxycorticosterone acetate-salt hypertensive rats. Hypertension. 1992;19(suppl II):II-98-II-104.
26. Li L, Fink GD, Watts SW, Northcott CA, Galligan JJ, Pagano PJ, Chen AF. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation. 2003;107:1053-1058.
27. Clozel M. Endothelin sensitivity and receptor binding in the aorta of spontaneously hypertensive rats. J Hypertens. 1989;7:913-917.
28. Chotani MA, Mitra S, Eid AH, Han SA, Flavahan NA. Distinct cAMP signaling pathways differentially regulate {alpha}2C-adrenoceptor expression: role in serum induction in human arteriolar smooth muscle cells. Am J Physiol Heart Circ Physiol. 2005;288:H69-H76.
29. Chen D, Balyakina EV, Lawrence M, Christman BW, Meyrick B. Cyclooxygenase is regulated by ET-1 and MAPKs in peripheral lung microvascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2003;284:L614-L621.
30. Baber SR, Deng W, Rodriguez J, Master RG, Bivalacqua TJ, Hyman AL, Kadowitz PJ. Vasoactive prostanoids are generated from arachidonic acid by COX-1 and COX-2 in the mouse. Am J Physiol Heart Circ Physiol. 2005;289:H1476-H1487.
31. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett. 1993;330:156-160.
32. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem. 2000;69:145-182.
33. Davidge ST. Prostaglandin H synthase and vascular function. Circ Res. 2001;89:650-660.
34. Bishop-Bailey D, Hla T, Mitchell JA. Cyclo-oxygenase-2 in vascular smooth muscle. Int J Mol Med. 1999;3:41-48.
35. Baker CS, Hall RJ, Evans TJ, Pomerance A, Maclouf J, Creminon C, Yacoub MH, Polak JM. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol. 1999;19:646-655.
36. Guo Z, Su W, Allen S, Pang H, Daugherty A, Smart E, Gong MC. COX-2 up-regulation and vascular smooth muscle contractile hyperreactivity in spontaneous diabetic db/db mice. Cardiovasc Res. 2005;67:723-735.
37. Stanke-Labesque F, Mallaret M, Lefebvre B, Hardy G, Caron F, Bessard G. 2-Arachidonoyl glycerol induces contraction of isolated rat aorta: role of cyclooxygenase-derived products. Cardiovasc Res. 2004;63:155-160.
38. Chen BC, Chang YS, Kang JC, Hsu MJ, Sheu JR, Chen TL, Teng CM, Lin CH. Peptidoglycan induces nuclear factor-kappaB activation and cyclooxygenase-2 expression via Ras, Raf-1, and ERK in RAW 264.7 macrophages. J Biol Chem. 2004;279:20889-20897.
39. Wu KK. Control of cyclooxygenase-2 transcriptional activation by proinflammatory mediators. Prostaglandins Leukot Essent Fatty Acids. 2005;72:89-93.
40. Yeo SJ, Gravis D, Yoon JG, Yi AK. Myeloid differentiation factor 88-dependent transcriptional regulation of cyclooxygenase-2 expression by CpG DNA: role of NF-kappaB and p38. J Biol Chem. 2003;278:22563-22573.
41. Mohan S, Hamuro M, Koyoma K, Sorescu GP, Jo H, Natarajan M. High glucose induced NF-kappaB DNA-binding activity in HAEC is maintained under low shear stress but inhibited under high shear stress: role of nitric oxide. Atherosclerosis. 2003;171:225-234.
42. Kobayashi N, Mita S, Yoshida K, Honda T, Kobayashi T, Hara K, Nakano S, Tsubokou Y, Matsuoka H. Celiprolol activates eNOS through the PI3K-Akt pathway and inhibits VCAM-1 Via NF-kappaB induced by oxidative stress. Hypertension. 2003;42:1004-1013.
43. Montagnani M, Potenza MA, Rinaldi R, Mansi G, Nacci C, Serio M, Vulpis V, Pirrelli A, Mitolo-Chieppa D. Functional characterization of endothelin receptors in hypertensive resistance vessels. J Hypertens. 1999;17:45-52.
44. Taddei S, Virdis A, Ghiadoni L, Salvetti A. Vascular effects of endothelin-1 in essential hypertension: relationship with cyclooxygenase-derived endothelium-dependent contracting factors and nitric oxide. J Cardiovasc Pharmacol. 2000;35:S37-S40.
45. Lin L, Nasjletti A. Prostanoid-mediated vascular contraction in normotensive and hypertensive rats. Eur J Pharmacol. 1992;220:49-53.
46. Li L, Chu Y, Fink GD, Engelhardt JF, Heistad DD, Chen AF. Endothelin-1 stimulates arterial VCAM-1 expression via NADPH oxidase-derived superoxide in mineralocorticoid hypertension. Hypertension. 2003;42:997-1003.